- Home
- CRT vs PSTV Comparison
CRT vs PSTV Comparison
Compare CRT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | PSTV |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 46.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CRT | PSTV |
|---|---|---|
| Price | $9.01 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 29.7K | ★ 6.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.59% | N/A |
| EPS Growth | N/A | ★ 44.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,824,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.87 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | ★ 18.54 |
| 52 Week Low | $7.07 | $0.16 |
| 52 Week High | $13.31 | $2.31 |
Technical Indicators
Market Signals| Indicator | CRT | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 49.43 |
| Support Level | $8.38 | $0.26 |
| Resistance Level | $9.17 | $0.32 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 81.87 | 57.68 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).